Dr Reddy's Laboratories, a Rs.13,200 crore plus second largest Indian pharma major, announces the launch of levalbuterol inhalation solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg/3 mL unit-dose vials, a therapeutic equivalent generic version of Xopenex (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (US FDA).
The Xopenex (levalbuterol hydrochloride) inhalation solution brand and generic combined had US sales of approximately $269.7 million MAT for the most recent twelve months ending in June 2014 according to IMS Health.
Dr Reddy’s levalbuterol inhalation solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL are available in unit-dose vials of (5 x 3 mL) carton of 25. Levalbuterol inhalation solution, USP is only for use with a nebulizer.